EDIT — Editas Medicine, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1650664 ·
Last close
$1.83
Market Cap
$281.67M
52W High
$3.94
52W Low
$1.66
ADV30
2,381,819
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 10,365,000 | — | -24,282,000 | -23,393,000 | 219,412,000 | 93,169,000 | 134,892,000 |
| Jun 2026 | 11,890,000 | — | -19,893,000 | -18,230,000 | 237,364,000 | 181,815,000 | 132,083,000 |
| Mar 2026 | 2,831,000 | — | -25,003,000 | -24,982,000 | 149,338,000 | 123,648,000 | 144,930,000 |
| Dec 2025 | 24,741,000 | — | -14,016,000 | -5,620,000 | 186,534,000 | 146,645,000 | 159,246,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-110,206,000
Investing CF
$-96,666,000
Financing CF
$134,393,000
CapEx
$-691,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.62
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,695,108,000
Inventory
—
Receivables
$7,727,000
ST Investments
$97,029,000
EBIT TTM
$-69,474,000
Pretax Income TTM
$-72,225,000
Interest Exp TTM
$2,751,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$49,827,000
EBITDA
$-81,105,000
Free Cash Flow
$-34,032,624
Enterprise Value
$158,660,256
Total Cash
$190,198,000
Total Debt
$13,941,000
Shares Out
154,339,748
Trailing EPS
$-0.54
Book Value
$0.55
ROE
-147.4%
ROA
-24.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 40,520,000 | -99,336,000 | -160,060,000 | 186,534,000 | 159,246,000 | 27,288,000 | -165,241,000 |
| Dec 2024 | 32,314,000 | -238,920,000 | -237,093,000 | 341,589,000 | 207,315,000 | 134,274,000 | -210,284,000 |
| Dec 2023 | 78,123,000 | -169,181,000 | -153,219,000 | 499,153,000 | 150,056,000 | 349,097,000 | -132,178,000 |
| Dec 2022 | 19,712,000 | -225,950,000 | -220,432,000 | 514,321,000 | 153,641,000 | 360,680,000 | -177,349,000 |
TTM Snapshot
Revenues TTM
$47,005,000
NetIncome TTM
$-73,949,000
OpCashFlow TTM
—
Assets (Latest)
$237,364,000
Forward EPS
$-0.72
Max Pain — expiry 2027-01-15
max pain strike: $2.00 · spot: $1.77 · call oi: 5,828 · put oi: 2,610
Expected Move to 2027-01-15:
±$0.80
(45.20%) —
implied range
$0.97 –
$2.57
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGEN | AGENUS INC | $280.98M | $6.21 | — |
| EIKN | Eikon Therapeutics, Inc. | $279.06M | $5.15 | — |
| TRXB | TRex Bio, Inc. | $274.46M | $10.00 | — |
| AUTL | Autolus Therapeutics plc | $290.12M | $1.09 | — |
| AGMB | AgomAb Therapeutics NV | $291.55M | $5.92 | — |
News headlines (Yahoo Finance, 1h cache)
Editas Medicine Plans Human Trial After Gene Therapy Slashed LDL 90% in Primate Study
2026-11-10 22:14 · Yahoo
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
2026-11-09 12:25 · Yahoo
Editas: Q3 Earnings Snapshot
2026-11-09 12:14 · Yahoo
Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and Intellia
2026-10-29 15:30 · Yahoo
Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference
2026-10-14 13:00 · Yahoo
EDIT Set to Begin First-in-Human Study in Hypercholesterolemia
2026-10-09 14:53 · Yahoo
Editas Medicine Gets Clearance For First Human Trial Of Gene-Editing Drug – Wells Fargo Sees Potential For Major Value Upside In 2027
2026-10-08 17:25 · Yahoo
Should You Pick Vertex Stock Over Its Biotech Rivals?
2026-11-18 17:13 · Yahoo
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?
2026-11-12 13:40 · Yahoo
What Will Decide Vertex Stock Over The Next Six Months?
2026-11-11 15:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.